Nothing Special   »   [go: up one dir, main page]

IL135751A - Process for identifying compounds capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor - Google Patents

Process for identifying compounds capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor

Info

Publication number
IL135751A
IL135751A IL135751A IL13575100A IL135751A IL 135751 A IL135751 A IL 135751A IL 135751 A IL135751 A IL 135751A IL 13575100 A IL13575100 A IL 13575100A IL 135751 A IL135751 A IL 135751A
Authority
IL
Israel
Prior art keywords
presenilins
precursor
beta
inhibiting
interaction
Prior art date
Application number
IL135751A
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9713384A external-priority patent/FR2770217B1/en
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL135751A publication Critical patent/IL135751A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
IL135751A 1997-10-24 2000-04-19 Process for identifying compounds capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor IL135751A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9713384A FR2770217B1 (en) 1997-10-24 1997-10-24 PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE PRECURSOR OF B-AMYLOID PEPTIDE AND / OR B-AMYLOID PEPTIDE
US9567198P 1998-08-07 1998-08-07
PCT/FR1998/002278 WO1999021886A1 (en) 1997-10-24 1998-10-23 PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE β-AMYLOID PEPTIDE OR ITS PRECURSOR

Publications (1)

Publication Number Publication Date
IL135751A true IL135751A (en) 2010-12-30

Family

ID=26233891

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13575198A IL135751A0 (en) 1997-10-24 1998-10-23 PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE β-AMYLOID PEPTIDE OR ITS PRECURSOR
IL135751A IL135751A (en) 1997-10-24 2000-04-19 Process for identifying compounds capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL13575198A IL135751A0 (en) 1997-10-24 1998-10-23 PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE β-AMYLOID PEPTIDE OR ITS PRECURSOR

Country Status (13)

Country Link
EP (1) EP1025121B1 (en)
JP (1) JP2001521043A (en)
KR (1) KR100626475B1 (en)
CN (1) CN100429230C (en)
AU (1) AU766522B2 (en)
BR (1) BR9813105A (en)
CA (1) CA2305816C (en)
CY (1) CY1112236T1 (en)
CZ (1) CZ303226B6 (en)
HU (1) HU227660B1 (en)
IL (2) IL135751A0 (en)
NO (1) NO328908B1 (en)
WO (1) WO1999021886A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2305816C (en) * 1997-10-24 2012-07-10 Aventis Pharma S.A. Peptides capable of inhibiting the interaction between presenilins and the .beta.-amyloid peptide or its precursor
DE19909357A1 (en) * 1999-03-03 2000-09-07 Gerd Multhaup Copper agonist that binds to the APP copper binding site and / or has an inhibitory effect on the release of the amyloid-Aß peptide
EP1259539A1 (en) * 2000-02-24 2002-11-27 Oxford GlycoSciences (UK) Limited Diagnosis and treatment of bipolar affective disorder
AU2002256687B2 (en) 2001-03-16 2007-01-11 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of binding domains of presenilins and transmembrane proteins for drug screening
JP2009533016A (en) * 2006-02-06 2009-09-17 イーラン ファーマスーティカルズ、インコーポレイテッド Presenilin 1 specific inhibitors and their use
US8129334B2 (en) * 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
CA2648096A1 (en) * 2006-03-31 2007-11-01 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
ES2530141B1 (en) * 2013-08-26 2016-01-15 Juan Carlos GALLAR RUIZ Peptide useful as a pharmacological target for the screening of molecules for the treatment and / or prevention of Alzheimer's disease, antibody against it and use of the antibody for the treatment and / or prevention of said disease.
CN108860921B (en) 2018-08-08 2020-11-20 上海鸿研物流技术有限公司 collapsible container

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877015A (en) * 1991-01-21 1999-03-02 Imperial College Of Science, Technology Of Medicine APP770 mutant in alzheimer's disease
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
EP0876483A1 (en) * 1996-01-26 1998-11-11 HSC Research and Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
CA2305816C (en) * 1997-10-24 2012-07-10 Aventis Pharma S.A. Peptides capable of inhibiting the interaction between presenilins and the .beta.-amyloid peptide or its precursor

Also Published As

Publication number Publication date
IL135751A0 (en) 2001-05-20
NO20002001L (en) 2000-04-17
HU227660B1 (en) 2011-10-28
AU766522B2 (en) 2003-10-16
CA2305816C (en) 2012-07-10
CN100429230C (en) 2008-10-29
CY1112236T1 (en) 2015-12-09
HUP0004605A1 (en) 2001-04-28
NO328908B1 (en) 2010-06-14
WO1999021886A1 (en) 1999-05-06
HUP0004605A3 (en) 2002-09-30
NO20002001D0 (en) 2000-04-17
CZ20001462A3 (en) 2000-10-11
AU3129500A (en) 2000-12-14
KR20010024541A (en) 2001-03-26
KR100626475B1 (en) 2006-09-20
EP1025121A1 (en) 2000-08-09
EP1025121B1 (en) 2011-08-24
JP2001521043A (en) 2001-11-06
CA2305816A1 (en) 1999-05-06
CZ303226B6 (en) 2012-06-06
CN1277616A (en) 2000-12-20
BR9813105A (en) 2000-08-15

Similar Documents

Publication Publication Date Title
IL129083A0 (en) Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis
IL130851A0 (en) Heterocyclic compounds and their use for inhibiting beta-amyloid peptide
EP0714810A3 (en) Key-in-ignition lock reminder system
MX195979B (en) Process for the polynitration of aromatic compounds
GB9603747D0 (en) Treatment of liquors
IL135751A (en) Process for identifying compounds capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor
GB9422391D0 (en) Oxidation of organosulphur compounds
GB2331239A9 (en) Cases covers or liners for articles of bedding
GB9717928D0 (en) Process for the enatioselective hydrolysis of n-derivatised lactams
IL131215A0 (en) Process for the manufacture of corks and corks manufactured using this process
ZA987741B (en) Process for the preparation of oxazaphosphorine-2-amines
HUP0001757A3 (en) Improved process for the preparation of halo-4-phenoxyquinolines
EP1038021A4 (en) Compounds and methods for the inhibition of protein-protein interactions
AU9240898A (en) Process for the modification of toxic and/or off-flavoured compounds
ZA989241B (en) Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides
GB9726223D0 (en) The treatment of materials
ZA978146B (en) Compound and process
KR100248098B1 (en) Pharmaceutical composition for the treatment of dementia
HUP0000770A2 (en) Process for the purification of substituted p-nitro-diphenyl-ethers
ZA9810979B (en) Arrangement and process for the reduction of metal-oxide-bearing material
IL132237A0 (en) Process for the preparation of 3-isochromanome
ZA981924B (en) Process for the preparation of n-carboxylalkyl-3-fluoro-4- dialkylaminoanilines
GB9714873D0 (en) Novel process and compound
GB9700693D0 (en) Novel process and compound
GB9602658D0 (en) Chemical compound and process

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees